Press Room

Event

Webinar: High performance solutions for DPI delivery: new formulation and device platforms

Start

Wednesday, October 04, 2023 - 16:00

Location: online

October 4th, 2023

11:00 am EDT | 4:00 pm GMT | 5:00 pm CEST | 8:00 am PDT

Registrations to the webinar are subject to approval.

Watch on-demand.

Featured Hovione experts in this webinar

Susana Saldanha, M.Sc. R&D Manager, Inhalation and Advanced Drug Delivery	Sofia Silva, M.Sc. R&D Manager, Analytical Development

This webinar will address the most relevant solutions for dry powder inhaler (DPI) development covering both formulation and device development, as well as process optimization and analytical characterization, under an integrated development approach.

DPIs are the dosage form of choice for delivering high doses of inhaled drugs and achieving maximum delivery efficiency to patients. This presentation will focus on new formulation platforms, aiming to address the pharmacokinetics requirements of the target drug and indication, coupled with a new high performance, high-dose device platform, the Sunriser® DPI.

This integrated approach is designed to maximize drug delivery efficiency while maintaining safety, and is able to address a diversified array of diseases.

Key Learning Objectives:

Gain insights on novel formulation development strategies for DPIs, to be able to improve drug delivery efficiency even with high drug loads;
Understand the potential of wet milling and dry milling capabilities for boosting the fine particle dose of DPI formulations;
Discover analytical characterization techniques, for differentiated formulations, to further understand product properties that impact drug delivery and aerodynamic performance;
Understand features associated with a novel high efficiency device platform, the Sunriser® capsule-based Dry Powder Inhaler;
Network with industry peers and experts during the live Q&A session.

Who Should Attend:

Pharmaceutical researchers and scientists
CMC experts on inhalation drug delivery
Business development, portfolio management and technology licensing experts
Inhalation product development professionals
Respiratory therapeutics specialists

Watch on-demand.

Our experts will reply to your questions during the live Q&A session.

Also in the Press Room

See All

International pharmaceutical contract development and manufacturing organisation (CDMO) Hovione has today officially commissioned an expansion at its manufacturing facility in Ringaskiddy. The multi-million euro investment almost doubles the capacity of Hovione’s spray drying facilities in Ireland and will create more than 20 new positions. Hovione said this latest investment reinforces the company's position as a global leader in spray drying for pharma applications. This manufacturing technology, the company explained, is "especially important for inhalable therapies and oral medications with low bioavailability, enabling more effective treatments". Deputising for the Mayor of the County of Cork, councillor Audrey Buckley said: “I am delighted to welcome this very significant investment and the creation of further highly skilled jobs in Cork today. “It reinforces Hovione’s commitment to the region and the innovative solutions it provides to the pharmaceutical industry in Ireland.” Meanwhile Michael McGrath, the European Commissioner-Designate for Democracy, Justice and the Rule of Law, welcomed the expected jobs boost the expansion is to create. “This latest investment highlights the success of Hovione’s facility in Ringaskiddy, and underlines the continued resilience of Ireland’s pharmaceutical manufacturing sector. “I am delighted that Hovione will be shortly welcoming new team members to this expanded facility, and I wish both them and Hovione every success”. Jean-Luc Herbeaux, Hovione's chief executive said: “This newly opened facility further strengthens Hovione's position as the global CDMO of choice for spray drying development and manufacturing services. “It also underscores our commitment to bringing first-in-class technology and world-leading manufacturing services to Irish shores. “Ireland provides a superior environment for pharmaceutical manufacturing, and we are delighted to be a part of it.” CEO of IDA Ireland, Michael Lohan, said Hovione "has made a significant contribution both locally and nationally through employment and investment alike". "We warmly welcome Hovione’s commitment to investing in Cork and we wish them continued success," he added. Read the full article on EchoLive.ie

Press Clipping

EchoLive, 25 November 2024

Pharma company announces expansion of Cork facility to create more than 20 new jobs

Nov 25, 2024

Pharmaceutical contract development and manufacturing company Hovione has officially commissioned an expansion at its manufacturing facility in Ringaskiddy, Cork. Announcing the development on Monday, the multi-million euro investment almost doubles the capacity of Hovione’s spray drying facilities in Ireland and will create more than 20 new positions. This manufacturing technology is especially important for inhalable therapies and oral medications with low bioavailability, enabling more effective treatments, the company said. Deputising for the Mayor of the County of Cork, Cllr. Audrey Buckley said: “I am delighted to welcome this very significant investment and the creation of further highly skilled jobs in Cork today. "It reinforces Hovione’s commitment to the region and the innovative solutions it provides to the pharmaceutical industry in Ireland.” Michael McGrath, the European Commissioner-Designate for Democracy, Justice and the Rule of Law said: “This latest investment highlights the success of Hovione’s facility in Ringaskiddy, and underlines the continued resilience of Ireland’s pharmaceutical manufacturing sector. "I am delighted that Hovione will be shortly welcoming new team members to this expanded facility, and I wish both them and Hovione every success”. This latest investment builds on the momentum of the recently announced spray drying capacity expansion at the Company's East Windsor, New Jersey, site. Jean-Luc Herbeaux, Hovione´s Chief Executive said: “This newly opened facility further strengthens Hovione´s position as the global CDMO of choice for spray drying development and manufacturing services. "It also underscores our commitment to bringing first-in-class technology and world-leading manufacturing services to Irish shores. Ireland provides a superior environment for pharmaceutical manufacturing, and we are delighted to be a part of it.” IDA chief executive Michael Lohan said the company has made a significant contribution both locally and nationally, adding: "I am pleased to be here today to mark another step on that journey. We warmly welcome Hovione’s commitment to investing in Cork and we wish them continued success.” Read the full article on IrishExaminer.com

Press Clipping

Irish Examiner, 25 November 2024

Pharma company Hovione to double capacity at Cork site as part multi-million euro investment

Nov 25, 2024

Hovione’s Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At Hovione we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook – “Trends in Formulation”. In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how Hovione is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa’s full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments. Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech

Article

Excipient and delivery device selection play crucial roles in the formulation of inhaled drugs.